DUGGAN ROBERT W 4
4 · Summit Therapeutics Inc. · Filed Sep 11, 2025
Insider Transaction Report
Form 4
DUGGAN ROBERT W
DirectorCo-Chief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
2025-09-11$18.07/sh+5,000$90,350→ 556,093,090 total - Purchase
Common Stock
2025-09-10$17.68/sh+333,394$5,894,406→ 556,088,090 total
Holdings
- 50,000(indirect: By Spouse)
Common Stock
- 25,457,666(indirect: By Trust)
Common Stock
- 31,000(indirect: By Spouse)
Common Stock
- 10,199,776(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.49 to $17.89 per share, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose